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aggregation (Citron et al., 1992, 1997; Lemere et al., 1996). The cause 
of modiﬁ  ed APP processing and Aβ 42 accumulation in sporadic 
cases of AD is unclear, but is likely to include oxidative stress (OS).
OS and Aβ are linked each other because Aβ induces OS in vivo 
and in vitro (Hensley et al., 1994; Mark et al., 1997; Murakami et al., 
2005; Tabner et al., 2005), and OS increases the production of Aβ 
(Paola et al., 2000; Tamagno et al., 2002; Tong et al., 2005).
OS increases is believed to be an early event in AD pathology 
(Nunomura et al., 2001; Cutler et al., 2004) as it contributes to 
membrane damage, cytoskeleton alterations and cell death (Perry 
et al., 2000).
Thus, the identiﬁ  cation of a large number of oxidatively modi-
ﬁ  ed proteins in common AD and AD animal models (Sultana 
et al.,  2009) suggests that OS plays an important role in AD 
pathogenesis.
Moreover, extensive oxidative damage observed in “mild cog-
nitive impairment” (MCI) brain regions (Lovell and Markesbery, 
2001) suggest that OS may be an early event in progression from 
normal aging to AD pathology. Based on these notions, it seems 
likely that increased production of oxygen free radicals (reactive 
oxygen species, ROS) may act as important mediators of synap-
tic loss and eventually promote neuroﬁ  brillary tangles and senile 
plaques formation (Kern and Behl, 2009).
Our studies, as described below, strengthen the hypothesis that 
OS may be a basic common pathway of Aβ accumulation and 
toxicity, which is in turn common to most AD risk factors (Zhu 
et al., 2004).
INTRODUCTION
Alzheimer’s disease (AD) is one of the most common age-related 
disorders (Bachman et al., 1993). AD is classiﬁ  ed into two forms: 
sporadic AD, which is correlated to aging, and a rare familial early-
onset AD (FAD), caused by gene mutations.
The pathological hallmarks of the disease are intraneuronal neu-
roﬁ  brillary tangles (NFTs) composed of hyperphosphorylated tau 
protein and deposition of amyloid-β (Aβ) ﬁ  brils in the extracellular 
space. Central to the disease is the altered proteolytic processing of 
the Aβ precursor protein (APP), resulting in overproduction and 
aggregation of neurotoxic forms of Aβ. APP is an integral mem-
brane protein with a single, membrane spanning domain, a large, 
extracellular, N-terminus, and a shorter, cytoplasmic C-terminus. 
The amyloidogenic processing of APP involves two sequential 
cleavages operated by the β- and γ-secretases at the N- and C-ter-
mini of Aβ respectively. The β-secretase (BACE1) cleaves APP at 
the beginning of the sequence of Aβ, generating an extracellular 
soluble fragment, called sβAPP, and an intracellular C-terminal 
end, termed C99. C99 is further cleaved, within the membrane, by 
the γ-secretase. The γ-cleavage produces Aβ fragments of different 
length, these being predominantly Aβ 40 and Aβ 42.
The central role of Aβ in the pathogenesis of AD is supported by 
two major clues. Aggregates of Aβ are neurotoxic and initiate a series 
of events, including the hyperphosphorylation of tau, which results 
in neuronal dysfunction and cell death (Yankner, 1996). All genes 
bearing mutations that cause FAD, APP and presenilins (PS) 1 and 
2, facilitate the accumulation of Aβ 42, increasing its production and 
Oxidative stress mediates the pathogenic effect of different 
Alzheimer’s disease risk factors
Michela Guglielmotto1, Luca Giliberto2, Elena Tamagno3* and Massimo Tabaton4
1  Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy
2  Litwin-Zucker Research Center for the Study of Alzheimer’s Disease, Manhasset, NY, USA
3 Scientiﬁ  c Institute of the Cavalieri-Ottolenghi Foundation, University of Turin, Turin, Italy
4  Department of Internal Medicine, University of Genoa, Genoa, Italy
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting the elderly 
population. Mechanistically, the major cause of the disease bases on the altered processing 
of the amyloid-β (Aβ) precursor protein (APP), resulting in the accumulation and aggregation 
of neurotoxic forms of Aβ. Aβ derives from the sequential proteolytic cleavage of the β- and 
γ-secretases on APP . The causes of Aβ accumulation in the common sporadic form of AD are 
not completely known, but they are likely to include oxidative stress (OS). OS and Aβ are linked 
to each other since Aβ aggregation induces OS in vivo and in vitro, and oxidant agents increase 
the production of Aβ. Moreover, OS produces several effects that may contribute to synaptic 
function and cell death in AD. We and others have shown that the expression and activity 
of β-secretase (named BACE1; β-site APP cleaving enzyme) is increased by oxidant agents 
and by lipid peroxidation product 4-hydroxynonenal and that there is a signiﬁ  cant correlation 
between BACE1 activity and oxidative markers in sporadic AD. OS results from several cellular 
insults such as aging, hyperglycemia, hypoxic insults that are all well known risk factors for AD 
development. Thus, our data strengthen the hypothesis that OS is a basic common pathway 
of Aβ accumulation, common to different AD risk factors.
Keywords: oxidative stress, Alzheimer’s disease, BACE1, Alzheimer’s risk factors, aging, hypoxia, hyperglycemia
Edited by:
Paula I. Moreira, University of Coimbra, 
Portugal
Reviewed by:
Rosa Resende, University of Coimbra, 
Portugal
Akihiko Nunomura, University of 
Yamanashi, Japan
*Correspondence:
Elena Tamagno, Department of 
Experimental Medicine and Oncology, 
University of Turin, Corso Raffaello 30, 
10125 Turin, Italy. 
e-mail: elena.tamagno@unito.itFrontiers in Aging Neuroscience  www.frontiersin.org  February 2010  | Volume 2  |  Article 3  |  2
Guglielmotto et al.  Oxidative stress and Alzheimer’s disease
Aβ AND OXIDATIVE STRESS
Growing attention has been focused on oxidative mechanisms 
of Aβ toxicity as well as the search for novel neuroprotective 
agents. The ability of toxic Aβ peptides to induce protein oxida-
tion and to inhibit the activity of oxidation-sensitive enzymes is 
consistent with the hypothesis that Aβ can induce severe oxida-
tive damage.
Transition metals, Cu(II), Zn(II) and Fe(III) favor the neu-
rotoxicity of Aβ, through their reduction, that yields hydrogen 
peroxide (H2O2) (Huang et al., 1999). Using density functional 
theory calculations, it has been shown that Aβ residue Tyr-10 
is a pivotal residue in driving the catalytic production of H2O2 
in the presence of Cu(II). It has been found that the phenoxy 
radical of Aβ Tyr-10 produced by the reaction with ROS causes 
neurotoxicity and results in the formation of dityrosines which, 
in turn, accelerate the aggregation of Aβ peptides (Barnham 
et al., 2004). Another crucial Aβ residue is Met-35; the substi-
tution of Met-35 with cysteine resulted in no protein oxida-
tion in C. elegans model (Yatin et al., 1999). Moreover, it has 
been suggested that inhibition of cytochrome c oxidase by Aβ 
42 could involve the formation of a redox active methionine 
radical (Crouch et al., 2006). Lipid peroxidation induced by Aβ 
peptides impairs the function of ion-motive ATPases, glucose 
and glutamate transporters and of GTP-binding proteins, as the 
result of their covalent modiﬁ  cation by aldehydic end products 
such as 4-hydroxynonenal (HNE) (Mattson, 1997). Moreover, 
toxic forms of aggregated Aβ peptides favor Ca2+ inﬂ  ux into neu-
rons by inducing membrane-associated OS, rendering neurons 
vulnerable to excitotoxicity and apoptosis (Bezprozvanny and 
Mattson, 2008). Aβ is able to create oxidative modiﬁ  cations of 
proteins involved in cellular defense mechanisms against noxious 
stimuli and in proteins involved in energy pathways. In a murine 
knock-in model of AD, entailing APP and PS1 mutations, a direct 
correlation was demonstrated between the excessive production 
of Aβ species and the impairment of antioxidant enzymes, with 
consequent mitochondrial dysfunction (Anantharaman et al., 
2006). These are further demonstrations of how increased OS 
caused by Aβ can lead to increased oxidative modiﬁ  cation of 
proteins and lipids, leading to impaired cellular function and cell 
death, and consequently to cognitive impairment and AD-like 
pathology (Sultana et al., 2009).
It is still controversial whether the most deleterious form of 
Aβ peptide in the early stage of AD is represented by the ﬁ  bril-
lar or the soluble oligomeric peptide form (Drouet et al., 2000). 
Recent literature data suggest that small soluble aggregates of Aβ, 
including protoﬁ  brils and oligomers, may be more toxic than Aβ 
ﬁ  brils (Gong et al., 2003; Kayed et al., 2003; Resende et al., 2008; 
Picone et al., 2009). These data may help explain, for example, why 
neurodegeneration and speciﬁ  c spatial learning deﬁ  cits may occur 
in AD animal models before the appearance of amyloid plaques 
(Chui et al., 1999; Koistinaho et al., 2001).
On the other hand OS may be also the cause of Aβ accu-
mulation. Oxidant agents and oxidative products increase APP 
expression (Cheng and Trombetta, 2004; Patil et al., 2006) and 
intracellular and secreted Aβ levels in neuronal and non neuronal 
cells like astrocytes (Frederikse et al., 1996; Misonou et al., 2000; 
Atwood et al., 2003; Murray et al., 2007). We and others have 
shown that the expression and activity of BACE1 is increased 
by oxidants (Tamagno et al., 2002, 2003, 2005; Kao et al., 2004; 
Tong et al., 2005). Moreover, there is a signiﬁ  cant correlation of 
BACE1 activity with oxidative markers in sporadic AD brain tis-
sue (Borghi et al., 2007), in which a signiﬁ  cant increase of BACE1 
expression has been shown (Fukumoto et al., 2002; Holsinger 
et al., 2002; Yang et al., 2003).
We have proposed that a sequence of events link OS, BACE1 
induction and apoptotic cell death through an overproduction of 
Aβ. Initially we have shown that oxidant agents and HNE signiﬁ  -
cantly increase the expression, protein levels and activity of BACE1 
in NT2 neurons, without affecting the levels of APP (Tamagno et al., 
2002, 2003). These events are followed by an overproduction of Aβ 
peptides as well as by morphological signs of apoptotic cell death 
(Tamagno et al., 2005).
Then, we have found that OS increases the γ-secretase activity 
in cultured cells and in vivo, and that the increased expression of 
BACE1 induced by OS is regulated by the γ-secretase (Tamagno 
et al., 2008). These results have major implications for the patho-
genesis of sporadic AD. First, they suggest that OS, as effect of aging, 
can increase the expression of both presenilin 1 (PS1) and BACE1, 
thereby enhancing Aβ production. OS is the only known factor able 
to augment the γ-secretase cleavage by increasing the expression of 
PS1, the catalytic subunit of the endoprotease.
Secondly, our data reveal the existence of a positive feedback 
loop in which increased γ-secretase activity results in up-regulation 
of BACE1 expression.
Recently, Minopoli et al. (2007) demonstrated a correlation 
between the induction of OS and the increase of γ-secretase cleav-
age on APP. Given that OS can mediate both γ-secretase and BACE1 
activities, we suggest that OS is the molecular link between β- and 
γ-secretase and that, as a consequence, the activities of the two 
endoproteases are also linked.
Our ﬁ  ndings suggested a sequence of pathological events that 
could contribute to the pathogenesis of the common, sporadic, late 
onset form of AD. In this review we will examine the role of OS in 
three of major risk factors for AD, such as aging, hypoxic insults 
(stroke) and hyperglycemia (diabetes mellitus). Our hypothesis 
is that OS could be considered a basic common pathway for Aβ 
accumulation induced by different AD risk factor.
OXIDATIVE STRESS IN AD AND AGING
The major non-genetic risk factor for development of late-onset 
sporadic AD is aging but the pathological circumstances causing 
it are still under debate.
OS increases with age through variations in ROS generation, 
ROS elimination or both (Barja, 2004). The free radical hypothesis 
of aging implies that accumulation of ROS results in damage of the 
major cell components: nucleus, mitochondrial DNA, membranes 
and cytoplasmic proteins (Harman, 1992). It has been proposed 
that mitochondria play a central role in this process because they 
are the primary site of ROS formation.
Oxidative damage impairs the cellular antioxidant defense caus-
ing a vicious cycle. Recently, the central role of OS in aging was 
further conﬁ  rmed by showing that the depletion of mitochondrial 
cysteine is directly correlated with life span in aerobic organisms 
(Moosmann and Behl, 2008).Frontiers in Aging Neuroscience  www.frontiersin.org  February 2010  | Volume 2  |  Article 3  |  3
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The brain is particularly vulnerable to OS because of its high 
consumption of oxygen, high levels of polyunsaturated fatty acids, 
and relatively low levels of antioxidants (Floyd and Hensley, 2002; 
Mattson et al., 2002). Accumulation of oxidative damage in the 
brain is particularly deleterious since it is a post-mitotic tissue with 
neurons exhibiting only a weak self-renewal potential due to their 
low proliferative capacity. An increased oxidative burden has been 
observed in the brain of non-demented elderly and of sporadic AD 
patients (Behl and Moosmann, 2002; Moosmann and Behl, 2002). 
Membrane lipids are commonly attacked by ROS and peroxidation 
of lipids is the most frequently analyzed oxidative marker that is 
increased during aging (Zhu et al., 2006).
The oxidative modiﬁ  cation of fatty acids leads to a structural 
damage membranes and to the generation of several aldehydic 
end products, such as HNE, which have a high oxidative poten-
tial themselves and can severely impair cellular function (Keller 
and Mattson, 1998). Post mortem analysis of the brains of AD 
patients found increased levels of lipid peroxidation in brain 
regions that are affected by an early neurodegeneration (Mielke 
and Lyketsos, 2006).
Several studies have shown that protein oxidation also increases 
exponentially with brain aging (Abd El Mohsen et al., 2005) and is 
associated with a decreased capacity of the antioxidative defense 
machinery (Rodrigues Siqueira et al., 2005). Importantly, also levels 
of oxidized proteins correlate with cognitive performance and AD 
patients exhibit increased levels of protein carbonylation, a key 
marker for protein oxidation (Keller et al., 2005).
Another well known age-dependent modiﬁ  cation is the oxida-
tive damage of DNA. Mutations in mitochondrial DNA cause a 
respiratory chain dysfunction, which can increase cellular OS. It 
is well established that mitochondrial mutations accumulate dur-
ing brain aging and neurodegenerative diseases (Corral-Debrinski 
et al., 1992; Wang et al., 2005).
Moreover, the extensive oxidative damage observed in “MCI” 
brain regions, considered a transition stage between normal aging 
and dementia, suggests that OS may be an early event in progression 
from normal aging to AD pathology (Sultana et al., 2009; Padurariu 
et al., 2010).
It has been shown that in MCI patients, plasma levels of non-
enzymatic antioxidants and activity of antioxidant enzymes 
appeared to be decreased when compared to those of controls 
(Guidi et al., 2006; Sultana et al., 2008), moreover, levels of oxi-
dative markers were showed increased (Lovell and Markesbery, 
2001; Williams et al., 2006; Cenini et al., 2008). Based on OS and 
histopathological similarities, studies of MCI may provide clues 
about AD pathogenesis and progression, as well as about the devel-
opment of therapeutics to treat or delay this disorder.
In summary, the oxidative burden observed in healthy brain 
aging and in early stages of Dementia, conﬁ  rms that the accumu-
lation of oxidatively modiﬁ  ed biomolecules is a general hallmark 
of brain aging and could be an early event in the progression of 
MCI to AD.
OXIDATIVE STRESS IN AD AND HYPOXIA
It is known that patients with stroke and cerebral infarction are at 
risk of AD (Rocchi et al., 2009). Hypoxia is a direct consequence of 
hypoperfusion, which plays a role in the Aβ accumulation.
Oxygen homeostasis is essential for the development and 
functioning of an organism. Prolonged and severe hypoxia can 
cause neuronal loss and memory impairment (Koistinaho and 
Koistinaho, 2005). Recent studies have shown that a history of 
stroke can increase AD prevalence by approximately twofold in 
elderly patients (Schneider et al., 2003; Vermeer et al., 2003). 
The risk is higher when stroke is concomitant with atheroscle-
rotic vascular risk factor (Jellinger, 2002). Recently, it has been 
proposed that hypoxia can alter APP processing, increasing the 
activity of the β- and the γ-secretases. Sun et al., (2006) showed 
that hypoxia signiﬁ  cantly up-regulates BACE1 gene expression, 
resulting in increased β-secretase activity. Moreover, the same 
Authors found that hypoxia increases Aβ deposition and neu-
ritic plaque formation, as well as memory deﬁ  cits, providing a 
molecular mechanistic link of vascular factors with AD. More 
recently, sequence analysis and gel shift assays revealed bind-
ing of hypoxia inducible factor (HIF)-1α, a molecule that regu-
lates oxygen homeostasis (Sharp and Bernaudin, 2004), to the 
BACE1 promoter. It has been demonstrated that overexpression 
of HIF-1α in neuronal cells increases BACE1 mRNA and protein 
levels (Zhang et al., 2007). Hypoxia was also found to increase 
γ-secretase activity: HIF-1α binds to the promoter of anterior 
pharynx-defective phenotype (APH-1), a key component of the 
γ-secretase complex, to up-regulate its expression (Wang et al., 
2006; Li et al., 2009).
Collectively these data show that hypoxia increases the β- and 
the γ-secretase activities, which facilitate the abnormal cleavage of 
APP, resulting in the acceleration of Aβ production and plaque 
formation both in vivo and in vitro.
Although it is generally accepted that intracellular ROS lev-
els change during hypoxia, the direction in which this change 
occurs is still debated. Levels of intracellular ROS increase under 
hypoxia (Chandel et al., 1998; Dirmeier et al., 2002; Guzy et al., 
2005). Chandel et al. (1998) suggested that mitochondria are the 
source of ROS involved in the hypoxic response. The electron 
transport chain, which is embedded in the inner membrane of 
mitochondria, consists of ﬁ  ve multiprotein complexes. Complexes 
I and II oxidize the energy-rich molecules NADH and FADH2, 
respectively, and transfer the resulting electrons across the inner 
mitochondrial membrane to cytochrome c, which carries them 
to complex IV. Complex IV uses the electrons to reduce oxygen 
to water. Along with carrying electrons, complexes I, II and III 
generate ROS (Turrens, 2003; Klimova and Chandel, 2008). It is 
now accepted that hypoxia increases ROS via the mitochondrial 
transport chain and speciﬁ  cally by the function of complex III 
(Bell et al., 2007).
The mitochondria-derived ROS are both necessary and sufﬁ  -
cient to stabilize and activate HIF-1α. It has been demonstrated that 
antioxidants reverse hypoxia-induced HIF-1α activation (Hwang 
et al., 2008). Recent anti-tumorigenic effects of antioxidants have 
been attributed to the inhibition of HIF-1α-dependent events (Gao 
et al., 2007). Moreover, the addition of oxidants, such as hydrogen 
peroxide, induces HIF-1α activity up-regulation in normoxia (Pagé 
et al., 2008).
We recently showed, both in vivo and in vitro, that hypoxia 
up-regulates BACE1 expression in a biphasic manner, through 
two distinct mechanisms: (1) an early release of ROS from Frontiers in Aging Neuroscience  www.frontiersin.org  February 2010  | Volume 2  |  Article 3  |  4
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  mitochondria and (2) a late activation of HIF-1α (Guglielmotto 
et al., 2009). The data suggests that the early post-hypoxic up-
regulation of BACE1 depends on the generation of ROS mediated 
by sudden interruption of the mitochondrial electron transport 
chain. The involvement of ROS released by mitochondria was 
conﬁ  rmed by complete protection exerted by compounds, such as 
rotenone and diphenyl-phenylen iodonium, that affect complex I 
of the mitochondrial electron transport chain (Li and Trush, 1998; 
Höglinger et al., 2005). This early post-hypoxic up-regulation of 
BACE1 recapitulates the cascade of events induced by oxidant 
agents and HNE both in vivo and in vitro (Tamagno et al., 2002, 
2005, 2008).
OXIDATIVE STRESS IN AD AND HYPERGLYCEMIA
Diabetes mellitus, a complex metabolic disorder characterized by 
hyperglycemia, is a risk factor for AD, and multiple mechanisms 
connecting the two diseases have been proposed (Granic et al., 2009; 
Jones et al., 2009; Kojro and Postina, 2009).
Hyperglycemia enhances the formation of advanced glycation 
end products (AGEs), senescent protein derivatives that result 
from the auto-oxidation of glucose and fructose (Bucala and 
Cerami, 1992). Thus, reducing sugars, such as fructose, glucose 
and glyceraldehyde are known to react non-enzymatically with 
the amino groups of proteins to form irreversible Schiff bases and 
then Amadori products (Takeuchi and Makita, 2001). The early 
glycation products undergo further complex reactions such as rear-
rangement, dehydration, and condensation to become irreversibly 
cross-linked, heterogeneous ﬂ  uorescent derivatives termed AGEs 
(Brownlee et al., 1988).
Accumulation of AGEs in various tissues is known to occur in 
normal aging, and, at an extremely accelerated rate, in diabetes mel-
litus and renal failure (Jerums et al., 2003; Ahmed and Thornalley, 
2007; Goh and Cooper, 2008). AGEs have been detected in vascular 
walls, lipoproteins and lipid constituents where they lead to macro 
and microangiopathy and amyloidosis (Schmidt et al., 1999; Gasser 
and Forbes, 2008).
The involvement of AGEs in brain aging and in AD was reported 
more than 10 years ago, in studies showing that the microtubule 
associated protein tau and Aβ, were substrates for glycation 
(Ledesma et al., 1994; Smith et al., 1994; Vitek et al., 1994; Yan et al., 
1994, 1995). Tau is preferentially glycated at its tubulin-binding site, 
suggesting that glycation may be one of the modiﬁ  cations able to 
hamper this interaction (Ledesma et al., 1994). Increased extracel-
lular AGEs formation was demonstrated in amyloid plaques in dif-
ferent cortical areas (Kimura et al., 1995), were they may have a role 
in accelerating the conversion of Aβ from monomers to oligomers 
or higher molecular weight forms (Loske et al., 2000).
Besides post-translational protein modiﬁ  cations, AGEs have 
other pathologic effects, at the cellular and molecular levels. 
Among these are the production of ROS, particularly superoxide 
and hydrogen peroxide (Carubelli et al., 1995; Ortwerth et al., 
1998; Muscat et al., 2007). Indeed, glycated proteins increase the 
rate of free radical production compared to the native proteins 
(Neeper et al., 1992).
Another mechanism through which AGEs mediate the 
 production of OS is the interaction with RAGE, which is a mul-
tiligand receptor of the immunoglobulin superfamily of cell 
surface molecules (Neeper et al., 1992; Schmidt et al., 1992; Qin 
et al., 2008).
RAGE is up-regulated in an age-dependent fashion in human 
tissue (Simm et al., 2004), and increased AGE-RAGE interaction 
causes OS which it believed to be relevant in the pathogenesis of 
many age-related diseases, such as diabetes, cardiovascular disease 
and AD (Heine and Dekker, 2002; Zlokovic, 2008).
The role of RAGE in the pathogenesis of AD has been exten-
sively studied, since it also binds Aβ (Yan et al., 1996), increasing 
its inﬂ  ux into the brain through the blood-brain barrier (Arancio 
et al., 2004; Takuma et al., 2009).
The role of RAGE in Aβ-mediated toxicity was assessed by in 
recent study performed using a murine transgenic model, with tar-
geted neuronal overexpression of RAGE and mutant APP (Arancio 
et al., 2004). These mice displayed early abnormalities in spatial 
learning/memory, accompanied by altered activation of markers 
of synaptic plasticity, and exacerbated neuropathological ﬁ  ndings, 
indicating that RAGE is an important co-factor for Aβ-induced 
neuronal perturbation.
Moreover, pre-treatment of cultured neurons from wild type 
mice with neutralizing antibody to RAGE determined decreased 
up-take of Aβ and protection from Aβ-mediated mitochondrial 
dysfunction (Takuma et al., 2009). Similar results are seen in RAGE 
knock-out neurons.
Very recently, a role of RAGE in the up-regulation of BACE1, 
the rate limiting enzyme of Aβ production, was reported in an 
AD animal model (Cho et al., 2009). BACE1 up-regulation was 
reported in cells over-expressing RAGE and in RAGE-injected 
brains of Tg2576 mice, harboring a human APP transgene with 
the Swedish mutation (Cho et al., 2009).
CONCLUSIONS
It is expected that, taken into account the increase in life expectancy, 
the population will continuously age in the next years and virtually 
everybody has a high probability to become demented. Although 
this correlation is obvious, the molecular details of the link between 
aging and cognitive decline are not fully understood. The data here 
reviewed strongly supported the hypothesis that OS could be a basic 
common pathway of Aβ accumulation, as determined by different 
age-related risk factors (Figure 1).
The links between aging and the development of subtle but 
continuous cellular changes, such as protein, nucleic acids and 
lipid oxidation have been known for years, and are ever so clear 
today. It is also evident how such changes have the potential to 
further undermine the cellular self defense strategies. In the case 
of AD, these events translate into different mechanisms that lead 
to impaired clearance, increased accumulation and aggregation of 
Aβ, and a series of molecular signals that lead to the up-regula-
tion of the enzymes that process APP to generate Aβ itself. In this 
view, if enough time is allowed for such events to take place, AD Frontiers in Aging Neuroscience  www.frontiersin.org  February 2010  | Volume 2  |  Article 3  |  5
Guglielmotto et al.  Oxidative stress and Alzheimer’s disease
pathology and dementia will eventually develop in every brain. 
The need to understand and control amyloid production and 
accumulation is ever so necessary now, as the world population 
is aging at a fast pace.
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